Prostate cancer patients who do not respond well to PSMA-targeted therapy often have potentially treatable mutations in their DNA damage-repair genes, according to research published in the May issue of The Journal of Nuclear Medicine.
from News Medical Medical Research News Feed https://ift.tt/2Tqp6uy
0 Comments